Press release – For immediate release – 5:45 pm CEST
Disclosure of total number of voting rights and number of shares in the capital as of July 31st, 2023, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
| Total number of shares | 18,270,608 |
| Number of real voting rights* (excluding treasury shares**) | 18,211,483 |
| Theoretical number of voting rights* (including treasury shares**) | 18,247,408 |
(**) pursuant to article 223-11 of the AMF’s General Regulations
Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and eyonis™, our AI/ML tech-based suite of software as medical devices (SaMD), help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world.